Year: 2024

Blue Mantis Acquires Colligio; Launches Collaboration/Unified Communications Practice

Written by Customer Service on November 19, 2024. Posted in Mergers And Acquisitions.

Acquisition Significantly Bolsters Blue Mantis’s Expertise and Capabilities in Delivering Best-in-Class UC Solutions to its Client Base PORTSMOUTH, N.H., Nov. 19, 2024 (GLOBE NEWSWIRE) — Blue Mantis, a leading provider of digital strategy and services specializing in managed services, cybersecurity, and cloud solutions, today announced that it has acquired Colligio, a provider of unified communications, networking and security solutions, specializing in Cisco-based technologies, headquartered in Walpole, MA with customers and employees located throughout the Northeast. With the acquisition, Blue Mantis is launching a new Collaboration/Unified Communications Practice, allowing it to take a more focused approach to delivering best-in-class collaboration and communication solutions, backed by world-class managed services. Colligio...

Star Equity Holdings, Inc. Announces 2024 Third Quarter Financial Results

Written by Customer Service on November 19, 2024. Posted in Earnings Releases And Operating Results.

Recent large commercial contract wins validate optimism for Building Solutions upturn Enservco investment diversifies portfolio; marks entry into Energy Services and Transportation & Logistics OLD GREENWICH, Conn., Nov. 19, 2024 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP) (“Star” or the “Company”), a diversified holding company, reported today its financial results for the third quarter (Q3) ended September 30, 2024. All 2024 and 2023 amounts in this release are unaudited. Following the sale of our Digirad Health business on May 4, 2023, all financial results for the 2023 reporting period, unless stated otherwise, relate to continuing operations, which currently include two divisions: Building Solutions (formerly known as Construction) and Investments. Q3 2024 Financial Highlights vs. Q3 2023 (unaudited)Revenues...

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences

Written by Customer Service on November 19, 2024. Posted in Public Companies.

BEDMINSTER, N.J., Nov. 19, 2024 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at three upcoming investor conferences: Evercore 7th Annual HealthCONx ConferenceTuesday, December 3, 2024 at 10:50 a.m. ET in Miami, FL Citi 2024 Global Healthcare ConferenceWednesday, December 4, 2024 at 3:15 p.m. ET in Miami, FL Piper Sandler 36th Annual Healthcare ConferenceThursday, December 5, 2024 at 11:30 a.m. ET in New York, NY A live and achieved webcast of the presentations can be accessed under “Events & Presentations” in the Investors section of the Company’s...

Digitalist Group Plc Oy – Managers’ Transactions

Written by Customer Service on November 19, 2024. Posted in Public Companies.

Digitalist Group Plc Oy – Managers’ Transactions Person subject to the notification requirement Name: Wilhelm Rosenlew Position: Member of the Board/Deputy member Issuer: Digitalist Group Plc Oy LEI: 743700AL68PUX6JMS644 Notification type: INITIAL NOTIFICATION Reference number: 84921/5/4 Transaction date: 2024-11-12 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN: FI0009008007 6 / 7Nature of transaction: DISPOSAL Transaction details (1): Volume: 440000 Unit price: 0.0182 EUR (2): Volume: 40000 Unit price: 0.0186 EUR (3): Volume: 40000 Unit price: 0.0182 EUR Aggregated transactions (3): Volume: 520000 Volume weighted average price: 0.01823 EURAdditional information: Digitalist Group Plc CEO Magnus Leijonborg, tel. +46 76 315 8422, magnus.leijonborg@digitalistgroup.com Chairman of the Board...

Hepsiburada to Announce Third Quarter 2024 Results on December 10, 2024

Written by Customer Service on November 19, 2024. Posted in Public Companies.

ISTANBUL, Nov. 19, 2024 (GLOBE NEWSWIRE) — D-MARKET Electronic Services & Trading (d/b/a “Hepsiburada”) (NASDAQ: HEPS), a leading Turkish e-commerce platform, will report its unaudited financial results for the third quarter ending September 30, 2024 before the U.S. market opens on Tuesday, December 10, 2024. Conference Call and Webcast DetailsHepsiburada’s management will host an analyst and investor conference call and live webcast to discuss its financial results at 16.00 İstanbul / 13.00 London / 8.00 a.m. New York time on Tuesday, December 10, 2024. Live webcast can be accessed via https://87399.themediaframe.eu/links/hepsiburada241210.html. A replay will be available on the Hepsiburada Investor Relations website https://investors.hepsiburada.com following the call. Hepsiburada’s results presentation will be available...

EDAP Announces Scientific Presentation at 2024 AAGL Global Congress Comparing Focal One HIFU Versus Surgery for the Treatment of Deep Infiltrating Endometriosis

Written by Customer Service on November 19, 2024. Posted in Public Companies.

Treatment with robotic HIFU showed reduction in moderate and severe post-operative complications and reduced hospital stay compared to surgeryLYON, France, November 19, 2024 – EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced a moderated scientific presentation of clinical data comparing Focal One HIFU versus surgery for the treatment of deep infiltrating endometriosis at the 2024 AAGL Global Congress, which took place from November 16-19, 2024, in New Orleans, LA. The presentation was entitled, “Evaluation of rectal endometriosis treatment with high-intensity focused ultrasound versus surgery: a retrospective multicenter study”, and was delivered by Professor Gil Dubernard, Head of Gynecology Department at Croix-Rousse University Hospital, Lyon, France, and...

Novartis ranks first in 2024 Access to Medicine Index

Written by Customer Service on November 19, 2024. Posted in Public Companies.

The Index spotlights Novartis leadership in research and development, and governance of access, with Novartis ranking first in these sub-topicsNovartis malaria access plans, widespread registration of products in LMICs, and inclusive business model to improve access to products in multiple countries were all highlighted as Best Practice across the industryNovartis has risen three places to secure the top spot on the 2024 Access to Medicine IndexBasel, November 19, 2024 – Novartis has ranked first in the 2024 Access to Medicine Index (ATMI) report published today, highlighting the company’s leadership in improving access to medicines around the world. The Index, published every two years, is an independent report that assesses 20 of the world’s largest research-based pharmaceutical companies on their efforts to improve access to...

Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference

Written by Customer Service on November 19, 2024. Posted in Public Companies.

SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Evercore 7th Annual HealthCONx Conference. Details are as follows: Event: Evercore 7th Annual HealthCONx ConferenceDate: Tuesday, December 3, 2024Time: 7:55 AM ET Format: Fireside chat Webcast: https://wsw.com/webcast/evercore44/cdtx/2373273 A replay of the presentation will be available in the Investors section on the Company’s website at www.cidara.com. The replay of the presentation will be available for 90 days. Cidara will also...

Magna Accelerates Hybrid Innovation With First Dedicated Drive System Award

Written by Customer Service on November 19, 2024. Posted in Public Companies.

Dedicated hybrid drive system brings high performance and sustainability to leading Chinese OEM New 800V solution ensures a smooth and comfortable experience in all driving conditions Scalable DHD Duo design integrates seamlessly across various vehicle models, enhancing energy efficiency and driving versatilityAURORA, Ontario, Nov. 19, 2024 (GLOBE NEWSWIRE) — As OEMs increasingly prioritize hybrid solutions globally within their broader electrification strategies, Magna has secured its first award for a Dedicated Hybrid Drive (DHD) Duo system with a leading Chinese OEM. This recognition underscores Magna’s commitment to innovation and sustainability, as well as the company’s flexible approach to supplying power to wheels.A Media Snippet accompanying this announcement is available by clicking on this link. Magna’s...

AIM ImmunoTech Announces Publication of Breast Cancer Data from Roswell Park Comprehensive Cancer Center in The Journal for ImmunoTherapy of Cancer

Written by Customer Service on November 19, 2024. Posted in Public Companies.

OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data were published on Roswell Park Comprehensive Cancer Center’s Phase 1 study evaluating AIM ImmunoTech’s drug Ampligen® (also known as rintatolimod) as a component of a chemokine-modulating (CKM) regimen in early-stage triple-negative breast cancer (TNBC). Results of the study were reported in The Journal for ImmunoTherapy of Cancer. “We are very excited with these promising results from our study of a new treatment combination for patients with this most highly aggressive form of breast cancer, triple-negative breast cancer,” said study principal investigator Shipra Gandhi, MD, Associate Professor of Oncology and staff physician in the Department of Medicine at Roswell Comprehensive Cancer Center....

Year: 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals